388082-76-6

Basic information

• Product Name: 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch
• Synonyms: 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch;5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)aMino)quinazolin-6-yl)furan-2-carbaldehydehydrochloride;5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydr
• CAS NO: 388082-76-6
• Molecular Formula: C₂₆H₁₇ClFN₃O₃*ClH
• Molecular Weight: 510.3438232
• Mol File: 388082-76-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch(388082-76-6)
• EPA Substance Registry System: 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydroch(388082-76-6)

Safety Data

• Hazardous Substances Data: 388082-76-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride is used as a research compound for the development of new drugs. Its complex structure and functional groups may offer unique opportunities for medicinal chemists to explore its potential as a therapeutic agent, particularly in the treatment of various diseases and conditions.
Used in Drug Design and Synthesis:
In the pharmaceutical industry, 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride is used as a key intermediate in the synthesis of various drug candidates. Its unique structural features, including the furan and quinazoline rings, as well as the chloro and fluorobenzyl groups, can be exploited to design and synthesize novel compounds with potential therapeutic applications.
Used in Biological Assays and Screening:
5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride can be employed in biological assays and high-throughput screening processes to evaluate its potential biological activities and interactions with various biological targets. This information can be valuable in guiding further optimization and development of the compound as a drug candidate.
Used in Medicinal Chemistry Education:
As a complex and structurally interesting compound, 5-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)furan-2-carbaldehyde hydrochloride can be used as a teaching tool in medicinal chemistry courses and workshops. It can help students understand the importance of molecular structure in drug design and the role of various functional groups in modulating the biological activity of a compound.

Upstream product

• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 98-01-1 furfural 
• 845271-71-8 N⁴-[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-quinazoline-4,6-diamine 
• 19815-16-8 4-chloro-6-nitro-quinazoline 
• 616-79-5 2-amino-5-nitro-benzoic acid 
• 6943-17-5 6-nitroquinazolin-4-ol 
• 851653-35-5 [3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-nitro-quinazolin-4-yl)-amine 

Downstream Products

• 231277-92-2 lapatanib 
• 388082-78-8 lapatinib ditosylate 

Relevant articles and documents

Method for synthesizing lapatinib or intermediate 5-(4-hydroxy quinazoline)-furan-2-formaldehyde of lapatinib

The invention relates to a method for synthesizing lapatinib or intermediate 5-(4-hydroxy quinazoline)-furan-2-formaldehyde of lapatinib. The method for synthesizing the intermediate comprises steps as follows: 4-hydroxy-6-nitro quinazoline reacts with hydrazine hydrate in a solvent in the presence of a catalytic amount of catalyst, and 4-hydroxy-6-amino quinazoline is prepared; 4-hydroxy-6-amino quinazoline reacts with furaldehyde in the solvent in presence of acid, sodium nitrite and a catalytic amount of catalyst, and the intermediate is prepared. The invention further relates to a method for synthesizing lapatinib and/or a lapatinib salt, a lapatinib intermediate and/or a pharmaceutically acceptable salt of the intermediate. The method is performed by using the intermediate synthesized with the method. The method has the advantages that steps are simplified, agents are cheap, available and high in utilization rate, heavy metal pollution is avoided, the reaction condition/operation requirement is lower and/or the yield is high and the like.

Method for synthesizing lapatinib or intermediate thereof

The invention relates to a method for synthesizing lapatinib or an intermediate thereof. The method for synthesizing the intermediate comprises the steps as follows: under the condition that a catalytic quantity of a catalyst exists in a solvent, 4-amino-5-(4-(3-chloro-4-(3-fluorobenzyloxy) phenylamino)-quinazoline reacts with furfural for preparation of 5-(4-(3-chloro-4-(3-fluorobenzyloxy) phenylamino)-quinazoline-6-yl)furyl-2-carboxaldehyde hydrochloride, and the intermediate is prepared. The invention further relates to a method for synthesizing lapatinib and/or salt of lapatinib, the intermediate of lapatinib and/or pharmaceutically acceptable salt of the intermediate, and the method is performed with the intermediate which is synthesized by the previous method. The method has the advantages that steps are simplified, a reagent is cheap, available and high in use ratio, pollution from heavy metal is avoided, and requirements for reaction conditions/operation are relatively low and/or the yield is high.

PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB

Provided are a process for preparing lapatinib and its pharmaceutically acceptable salt by use of new intermediates, and a process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate.

Quinazoline ditosylate salt compounds

Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.